Actavis renews bidding war for Pliva

Ignoring Pliva's endorsement of a buyout offer from Barr Pharmaceuticals, the Actavis Group has upped its bid to $2.3 billion and insists it will win in the end. Actavis has acquired more than 20 percent of Pliva's shares and says that it believes the board will be happy to accept the highest offer for the Croatian generic drug company. If Actavis prevails, it will create the world's third largest generic drug maker, behind Teva and Novartis.

- here's the report on Actavis from the International Herald Tribune

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.